Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A

M. Porta, G. Maggioni, F. Ottaviani, A. Schindler

Research output: Contribution to journalArticlepeer-review


We assessed the effect of botulinum toxin type A (BTX-A) on phonic tics in patients with Tourette's syndrome. A total of 30 patients received 2.5 IU BTX-A (BOTOX; Allergan) in both vocal cords. All patients were assessed after 15 days and then 4 times over a 12-month period. At each visit the following data were collected: phenomenology of tics, global impression of changes by physician and patient, number of BTX-A injections given, interval between injections, time to response, duration of response, presence of post-injection hypophonia and side effects, presence of premonitory sensory tic component, and interference with social life and work or school activities. Vocal tics improved after treatment in 93% patients, with 50% being tic-free. Mean response time was 5.8 days, and mean duration of response was 102 days. Quality of life improved, and premonitory experiences dropped from 53% to 20%. Hypophonia was the only side effect of note (80% of patients). BTX-A is an effective and safe treatment for phonic tics associated with Tourette's syndrome.

Original languageEnglish
Pages (from-to)420-423
Number of pages4
JournalNeurological Sciences
Issue number6
Publication statusPublished - Feb 2004


  • Botox
  • Botulinum toxin type A
  • Phonic tics
  • Tourette's syndrome

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A'. Together they form a unique fingerprint.

Cite this